

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
April 27, 2018**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Vascular Biogenics Ltd.

File No. 1-36581 - CF#36111

Vascular Biogenics Ltd. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 20-F filed on March 15, 2018.

Based on representations by Vascular Biogenics Ltd. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 4.20	through March 15, 2028
Exhibit 4.21	through March 15, 2028
Exhibit 4.22	through March 15, 2028

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary